Affordable Access

Publisher Website

Neuroendocrine insights into neurosteroid therapy for postpartum depression.

Authors
  • Reddy, Doodipala Samba1
  • 1 Department of Neuroscience and Experimental Therapeutics, Texas A&M University School of Medicine, Bryan, TX 77807, USA; Texas A&M Health Institute of Pharmacology and Neurotherapeutics, Texas A&M University Health Science Center, Bryan, TX 77807, USA. Electronic address: [email protected].
Type
Published Article
Journal
Trends in molecular medicine
Publication Date
Dec 01, 2023
Volume
29
Issue
12
Pages
979–982
Identifiers
DOI: 10.1016/j.molmed.2023.07.006
PMID: 37541828
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Postpartum depression (PPD) is associated with a decline in progesterone-derived anxiolytic-antidepressant neurosteroids after delivery. Neurosteroid replacement therapy (NRT) with GABA-A receptor-modulating allopregnanolone (brexanolone) shows promise as the first drug treatment for PPD. Here we describe the molecular insights of the neurosteroid approach for rapid relief of PPD symptoms compared with traditional antidepressants. Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 02/12/2024 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/37541828
Report this publication

Statistics

Seen <100 times